Effectiveness of 8- and 12-Week Treatment with Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve HCV Patients in a Real-Life Setting in Romania: the AMETHYST Study
| Autor: | Mihaela-Catalina Luca, Carol Stanciu, Zeno-Adrian Sparchez, Laura Iliescu, Cristina Cijevschi, Liliana Gheorghe, Liliana Baroiu, Cristina Pojoga, Mircea Diculescu, Ioan Sporea, Egidia Miftode, Adrian Streinu-Cercel, Catalina Mihai, Anca Trifan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Cyclopropanes Liver Cirrhosis Male medicine.medical_specialty Time Factors Proline Lactams Macrocyclic Antiviral Agents chemistry.chemical_compound Internal medicine Ombitasvir/paritaprevir/ritonavir 2-Naphthylamine medicine Humans Anilides Uracil Aged Retrospective Studies Aged 80 and over Sulfonamides Dasabuvir Ritonavir business.industry Romania Gastroenterology Valine Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Ombitasvir Regimen chemistry Tolerability Paritaprevir Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Journal of gastrointestinal and liver diseases : JGLD. 30(1) |
| ISSN: | 1842-1121 |
| Popis: | Background and Aims: The 12-week regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir (OPrD) has shown high efficacy and tolerability in clinical trials for the treatment of chronic hepatitis C virus (HCV). The shorter 8-week regimen has been recently incorporated into clinical guidelines and on-label indications, but real-world evidence on its use is limited. Given this knowledge gap, the AMETHYST study aimed to evaluate the effectiveness of the 8- and 12-week regimens of OPrD in treatment-naive patients with HCV with mild to moderate liver fibrosis in Romanian clinical practice. Methods: This was a secondary data collection study analyzing data from a 1-year Patient Support Program in HCV in Romania. Patients received OPrD treatment for 8 or 12 weeks. The effectiveness endpoint was sustained virologic response 12 weeks post-treatment (SVR12). Results: A total of 1,835 treatment-naive patients with HCV with mild or moderate fibrosis were included in the study. Of these, 426 and 1,375 completed the 8-week and 12-week regimens, respectively. SVR12 was 98.1% in the 8-week treatment group and 98.7% in the 12-week treatment group. Conclusion: The study provides real-world evidence that 8-week and 12-week treatment regimens of OPrD are highly effective in treatment-naive patients with HCV with mild to moderate liver fibrosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|